Charles Lopez

Associate Professor

  • 881 Citations
  • 16 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Charles Lopez is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Apoptosis Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
Proteins Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2000 2010

Apoptosis
Proteins
Neoplasms
Carrier Proteins
Proteins
DNA Damage
Neoplasms
Up-Regulation

Research Output 1990 2019

  • 881 Citations
  • 16 h-Index
  • 32 Article
  • 2 Review article
5 Citations (Scopus)

Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma

Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C., Sheppard, B., Christensen, D. J., Ohlmeyer, M., Narla, G. & Sears, R., Jan 1 2019, In : Cancer Research. 79, 1, p. 209-219 11 p.

Research output: Contribution to journalArticle

Protein Phosphatase 2
Adenocarcinoma
Phosphoric Monoester Hydrolases
Phosphotransferases
Growth

Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia

Schittenhelm, M. M., Walter, B., Tsintari, V., Federmann, B., Bajrami Saipi, M., Akmut, F., Illing, B., Mau-Holzmann, U., Fend, F., Lopez, C. & Kampa-Schittenhelm, K. M., Apr 1 2019, In : EBioMedicine. 42, p. 340-351 12 p.

Research output: Contribution to journalArticle

Open Access
Tumor Suppressor Protein p53
Alternative Splicing
Tumors
Protein Isoforms
Leukemia

A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer

Kearney, M. R., Chen, E. Y., Vaccaro, G., Strother, J., Burt, A., Todd, K., Donovan, J., Kampa-Schittenhelm, K. M. & Lopez, C., Jan 1 2019, In : Anticancer Research. 39, 1, p. 245-252 8 p.

Research output: Contribution to journalArticle

irinotecan
Colorectal Neoplasms
oxaliplatin
Neutropenia
Combination Drug Therapy
5 Citations (Scopus)

A Phase II Study of Celecoxib with Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Previously Untreated Advanced or Metastatic Colorectal Cancer

Chen, E. Y., Blanke, C., Haller, D. G., Benson, A. B., Dragovich, T., Lenz, H. J., Robles, C., Li, H., Mori, M. T., Mattek, N., Sanborn, R. E. & Lopez, C., Dec 1 2018, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 41, 12, p. 1193-1198 6 p.

Research output: Contribution to journalArticle

irinotecan
Celecoxib
Leucovorin
Fluorouracil
Colorectal Neoplasms
15 Citations (Scopus)

Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival

Gast, C. E., Silk, A. D., Zarour, L., Riegler, L., Burkhart, J. G., Gustafson, K. T., Parappilly, M. S., Roh-Johnson, M., Goodman, J. R., Olson, B., Schmidt, M., Swain, J. R., Davies, P., Shasthri, V., Iizuka, S., Flynn, P., Watson, S., Korkola, J., Courtneidge, S., Fischer, J. & 8 others, Jaboin, J., Billingsley, K., Lopez, C., Burchard, J., Gray, J., Coussens, L., Sheppard, B. & Wong, M., Sep 12 2018, In : Science advances. 4, 9, eaat7828.

Research output: Contribution to journalArticle

Cell Fusion
Hybrid Cells
Survival
Neoplasms
Biomarkers